fingolimod hydrochloride has been researched along with citraconic acid in 1 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (citraconic acid) | Trials (citraconic acid) | Recent Studies (post-2010) (citraconic acid) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 82 | 1 | 55 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hahn, JN; Kaushik, DK; Mishra, MK; Silva, C; Wang, J; Yong, VW | 1 |
1 other study(ies) available for fingolimod hydrochloride and citraconic acid
| Article | Year |
|---|---|
Impact of Minocycline on Extracellular Matrix Metalloproteinase Inducer, a Factor Implicated in Multiple Sclerosis Immunopathogenesis.
Topics: Animals; Anti-Bacterial Agents; Basigin; Central Nervous System; Clinical Trials, Phase III as Topic; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Interferon-beta; Lymphocyte Activation; Maleates; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Minocycline; Monocytes; Multiple Sclerosis; T-Lymphocytes; Tissue Inhibitor of Metalloproteinase-1 | 2016 |